Clinical Trials Logo

Non-Hodgkin Lymphoma, Adult clinical trials

View clinical trials related to Non-Hodgkin Lymphoma, Adult.

Filter by:
  • None
  • Page 1

NCT ID: NCT05798897 Recruiting - Hodgkin Lymphoma Clinical Trials

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

APOLLO
Start date: January 2, 2023
Phase: Phase 1
Study type: Interventional

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10^6 cells (flat dosing).

NCT ID: NCT04328844 Active, not recruiting - NSCLC Clinical Trials

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Start date: February 25, 2020
Phase: Phase 1
Study type: Interventional

The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)

NCT ID: NCT04292626 Completed - Clinical trials for Hodgkin Lymphoma, Adult

Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose

Start date: January 19, 2020
Phase: Phase 1
Study type: Interventional

The study should evaluate the biological distribution of 99mTc-1-thio-D-glucose in patients with Hodgkin Lymphoma and Non Hodgkin Lymphoma. The primary objective are: 1. To assess the distribution of 99mTc-1-thio-D-glucose in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of 99mTc-1-thio-D-glucose. 3. To study the safety and tolerability of the drug 99mTc-1-thio-D-glucose after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained 99mTc-1-thio-D-glucose SPECT imaging results with the data of CT imaging and/or 18F-FDG positron emission tomography (PET) and immunohistochemical (IHC) studies in Lymphoma patients.